---
title: "LifeMD Pref Share LFMDP 8.875 Perp 10/15/22 | 8-K: FY2025 Q2 Revenue: USD 62.22 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251699972.md"
datetime: "2025-08-05T20:12:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251699972.md)
  - [en](https://longbridge.com/en/news/251699972.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251699972.md)
generator: "portal-rs"
---

# LifeMD Pref Share LFMDP 8.875 Perp 10/15/22 | 8-K: FY2025 Q2 Revenue: USD 62.22 M

Revenue: As of FY2025 Q2, the actual value is USD 62.22 M.

EPS: As of FY2025 Q2, the actual value is USD -0.06.

#### Segment Revenue

-   **Total Revenue**: Increased 23% year-over-year to $62.2 million, driven by a 30% increase in telehealth revenue.
-   **Telehealth Revenue**: Increased 30% to $48.6 million.
-   **WorkSimpli Revenue**: Increased 3% to $13.7 million.

#### Operational Metrics

-   **Net Loss**: GAAP net loss was $2.9 million or - $0.06 per share, compared to a net loss of $7.7 million or - $0.19 per share in the prior-year period.
-   **Gross Margin**: 88%, compared to 90% in the prior-year period due to revenue mix.
-   **Adjusted EBITDA**: Increased 223% to $7.1 million, compared to $2.2 million in the prior-year period.
-   **Telehealth Adjusted EBITDA**: Increased 560% to $3.4 million, compared to $0.5 million in the prior-year period.

#### Cash Flow

-   **Operating Cash Flow**: Generated more than $8 million of operating cash flow.
-   **Cash Position**: Exited the quarter with $36.2 million in cash, inclusive of paying down $2.1 million of senior debt during the quarter.

#### Unique Metrics

-   **Active Telehealth Subscribers**: Increased 16% to approximately 297,000 at quarter-end.

#### Outlook / Guidance

-   **Third Quarter 2025 Guidance**: Total revenue expected in the range of $61 million to $63 million, with telehealth revenue in the range of $48 million to $50 million.
-   **Full Year 2025 Guidance**: Total revenue expected in the range of $250 million to $255 million, revised from previous guidance of $268 million to $275 million.
-   **Telehealth Adjusted EBITDA**: Forecasted to be in the range of $14 million to $16 million, down from $21 million previously.

### Related Stocks

- [LFMDP.US](https://longbridge.com/en/quote/LFMDP.US.md)

## Related News & Research

- [LifeMD Appoints Atul Kavthekar CFO As Marc Benathen Departs; Names Pisano CMO, Friedeman CBO](https://longbridge.com/en/news/279270079.md)
- [Inside Coca-Cola’s secretive innovation labs: How the beverage giant wants to automate dirty soda and refreshers](https://longbridge.com/en/news/296681725.md)
- [Powerful Growth, Multiple Endorsements Bode Well for Oracle Stock](https://longbridge.com/en/news/296686709.md)
- [TRB Wealth Management LLC Makes New $828,000 Investment in Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/296680142.md)
- [William Blair Investment Management LLC Buys Shares of 379,732 Mercury Systems Inc $MRCY](https://longbridge.com/en/news/296680261.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**